Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.9303
+0.0261 (2.89%)
At close: Oct 2, 2026, 4:00 PM EDT
0.9300
-0.0003 (-0.03%)
Pre-market: Oct 5, 2026, 7:50 AM EDT
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Lineage Cell Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.50. The average 1-year stock price forecast is 491.21% higher than the current stock price, while the lowest is $3.00 (+222.48%) and the highest is $9.00 (+867.43%).
Price Target: $5.50 (+491.21%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Buy Maintains $4 | Buy | Maintains | $4 | +329.97% | Sep 25, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $3 | Buy | Maintains | $3 | +222.48% | Aug 12, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $9 | Buy | Maintains | $9 | +867.43% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $7 → $9 | Buy | Reiterates | $7 → $9 | +867.43% | Aug 7, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 15, 2026 |
Financial Forecast
Revenue This Year
15.19M
from 14.56M
Increased by 4.38%
Revenue Next Year
16.83M
from 15.19M
Increased by 10.80%
EPS This Year
-0.07
from -0.22
EPS Next Year
-0.14
from -0.07
EPS and Forward PE are based on non-GAAP adjusted numbers.